ArticleDrug design, development and therapy2023
The Protective Effect of Selenium Nanoparticles in Osteoarthritis: In vitro and in vivo Studies.
Article in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Metabolic-Redox Remodeling of Inflammatory Synovium by Mannose-Modified Selenium Nanoparticles for Osteoarthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Selenium, Selenoprotein P, and Gut Dysbiosis are Associated with Cartilage Damage in Osteoarthritis Patients.Biological trace element research · 2026Article
- Signal-driven interplay between lipid peroxidation and ferroptosis orchestrates osteoarthritis degeneration.Journal of orthopaedic translation · 2026Review
- In vitro biological potential of green-synthesized nanoparticles from the Egyptian edible bivalve Paratapes undulatus (Born, 1778).Scientific reports · 2026Article
- Phycocyanin-functionalized selenium nanoparticles attenuate osteoarthritis through ferroptosis suppression and modulation of the MAPK pathway.Materials today. Bio · 2026Article
- Streptomyces thermolilacinus-mediated synthesis of Selenium Nanoparticles as biocompatible anti-inflammatory agent; characterization, radiolabeling, in vitro and in vivo evaluations.Folia microbiologica · 2026Article
- Selenium-loaded sustained-release schizophyllan alleviates pancreatic and pulmonary inflammatory damage in type 1 diabetes mellitus by modulating gut microbiota and T cell balance.Journal of nanobiotechnology · 2026Article
- Chondroitin Sulfate A-Selenium Nanoparticles Activate Autophagy Through the AMPK-mTOR Pathway to Alleviate Oxidative Stress and Mitochondrial Dysfunction to Repair Kashin-Beck Disease Chondrocytes.Biological trace element research · 2026Article
- Nanozyme-Integrated Hydrogel Targeting AGEs for Diabetic Osteoarthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mitochondrial-targeted therapy for osteoarthritis: Challenges and opportunities from basic research to clinical translation.Frontiers in immunology · 2026Review
- Article
- Marine actinobacterium Streptomyces vinaceusdrappus mediated nano-selenium: biosynthesis and biomedical activities.BMC complementary medicine and therapies · 2025Article
- Elemental Influence: The Emerging Role of Zinc, Copper, and Selenium in Osteoarthritis.Nutrients · 2025Review
- Mechanisms and Therapeutic Potential of GPX4 in Pain Modulation.Pain and therapy · 2025Review
- Selenium-containing nanoparticles and bone related disorders: from synthesis, bone metabolism to disease therapy.Frontiers in endocrinology · 2025Review
- Nanomaterial-Based Drug Delivery Systems Targeting Functional Cells for Osteoarthritis Treatment: Mechanisms, Challenges and Future Prospects.International journal of nanomedicine · 2025Review
- In vivo evaluation of selenium-tellurium based nanoparticles as a novel treatment for bovine mastitis.Journal of animal science and biotechnology · 2024Article
- Orthopedic revolution: The emerging role of nanotechnology.World journal of orthopedics · 2024Review
- Ferroptosis: a new regulatory mechanism in neuropathic pain.Frontiers in aging neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is a common chronic joint disease characterized by articular cartilage degeneration. OA usually manifests as joint pain, limited mobility, and joint effusion. Currently, the primary OA treatment is non-steroidal anti-inflammatory drugs (NSAIDs). Although they can alleviate the disease's clinical symptoms and signs, the drugs have some side effects. Selenium nanoparticles (SeNPs) may be an alternative to relieve OA symptoms. Materials and Results: We confirmed the anti-inflammatory effect of selenium nanoparticles (SeNPs) in vitro and in vivo experiments for OA disease in this study. In vitro experiments, we found that SeNPs could significantly reduce the expression of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), the major inflammatory factors, and had significant anti-inflammatory and anti-arthritic effects. SeNPs can inhibit reactive oxygen species (ROS) production and increased glutathione peroxidase (GPx) activity in interleukin-1beta (IL-1β)-stimulated cells. Additionally, SeNPs down-regulated matrix metalloproteinase-13 (MMP-13) and thrombospondin motifs 5 (ADAMTS-5) expressions, while up-regulated type II collagen (COL-2) and aggrecan (ACAN) expressions stimulated by IL-1β. The findings also indicated that SeNPs may exert their effects through suppressing the NF-κB p65 and p38/MAPK pathways. In vivo experiments, the prevention of OA development brought on by SeNPs was demonstrated using a DMM model. Discussion: Our results suggest that SeNPs may be a potential anti-inflammatory agent for treating OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.